Celltrion Wins Korea Approval For Roche Herceptin Biosimilar
This article was originally published in The Pink Sheet Daily
Executive Summary
Celltrion gains approval for its second monoclonal antibody biosimilar following a biosimilar of Johnson & Johnson’s Remicade. The approval marks the second entry of a Herceptin biosimilar and the first based on global clinical trials, but Roche believes it is adequately protected against the competition.
You may also be interested in...
Samsung Bioepis Files Biosimilar Enbrel In South Korea
Samsung Bioepis has applied for the approval in South Korea of production and sales of SB4, its biosimilar version of Amgen Inc.’s arthritis blockbuster Enbrel (etanercept).
Beyond Herceptin, Roche Readies Breast Cancer Successors, Braces For Biosimilars
Up-and-coming candidate T-DM1 shows an efficacy advantage in the Phase III EMILIA study, offers significantly better side effect profile and improved quality of life.
Early-Stage Idiopathic Pulmonary Fibrosis (IPF) Candidates Race to Phase III
Multiple IPF drugs are being rushed into Phase III based on early-stage signals of efficacy and safety presented at the ATS meeting. Scrip spoke with the University of Pittsburgh's Kevin Gibson about the candidates, trial design, combination therapy and limitations of current therapy.